Sino takes out the rest of Merck’s partner
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.